MedTrace Logo

Real-life-persistence to Antifibrotic Treatments

NCT06485635 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 10646

Last updated 2026-04-15

No results posted yet for this study

Summary

This study will help to better understand the persistence rate to antifibrotic (AF) treatment in real life in France and to identify potential areas for improvement by investigating the factors associated with a non-persistence rate to AF treatment.

Primary objective of the study is to measure the percentage of patients still treated up to 30 months after AF treatment initiation.

Conditions

Interventions

DRUG

Nintedanib

Nintedanib

DRUG

Pirfenidone

Pirfenidone

Sponsors & Collaborators

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-16
Primary Completion
2026-04-07
Completion
2026-04-07

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06485635 on ClinicalTrials.gov